DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,117 filers reported holding DANAHER CORPORATION in Q3 2017. The put-call ratio across all filers is 0.49 and the average weighting 0.5%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $9,018,085 | +1.3% | 36,094 | +1.2% | 2.82% | -0.8% |
Q1 2024 | $8,904,266 | +4.2% | 35,657 | -3.4% | 2.84% | +3.2% |
Q4 2023 | $8,542,692 | -1.7% | 36,927 | +5.4% | 2.75% | -8.7% |
Q3 2023 | $8,693,424 | +5.2% | 35,040 | +1.8% | 3.02% | +11.5% |
Q2 2023 | $8,264,400 | -4.3% | 34,435 | +0.5% | 2.70% | -10.0% |
Q1 2023 | $8,639,931 | -5.3% | 34,280 | -0.3% | 3.01% | -10.0% |
Q4 2022 | $9,124,079 | +2.5% | 34,376 | -0.2% | 3.34% | -8.0% |
Q3 2022 | $8,900,000 | -0.0% | 34,461 | -1.8% | 3.63% | +5.4% |
Q2 2022 | $8,901,000 | -14.8% | 35,110 | -1.4% | 3.45% | +2.2% |
Q1 2022 | $10,444,000 | -10.2% | 35,605 | +0.7% | 3.37% | -4.5% |
Q4 2021 | $11,627,000 | +1.5% | 35,344 | -6.0% | 3.53% | -1.7% |
Q3 2021 | $11,452,000 | +6.0% | 37,617 | -6.6% | 3.59% | +7.7% |
Q2 2021 | $10,806,000 | +15.3% | 40,267 | -3.3% | 3.33% | +10.2% |
Q1 2021 | $9,373,000 | +0.9% | 41,648 | -0.4% | 3.03% | -2.1% |
Q4 2020 | $9,286,000 | -1.4% | 41,798 | -4.4% | 3.09% | -7.5% |
Q3 2020 | $9,417,000 | +15.9% | 43,729 | -4.8% | 3.34% | +7.8% |
Q2 2020 | $8,124,000 | +25.2% | 45,941 | -2.0% | 3.10% | +5.2% |
Q1 2020 | $6,487,000 | -13.6% | 46,866 | -4.2% | 2.94% | +6.7% |
Q4 2019 | $7,504,000 | +4.8% | 48,896 | -1.4% | 2.76% | -2.1% |
Q3 2019 | $7,160,000 | +1.9% | 49,577 | +0.9% | 2.82% | +0.2% |
Q2 2019 | $7,027,000 | +5.4% | 49,154 | -2.6% | 2.82% | +4.0% |
Q1 2019 | $6,665,000 | +21.0% | 50,490 | -5.5% | 2.71% | +11.4% |
Q4 2018 | $5,509,000 | -7.1% | 53,425 | -2.1% | 2.43% | +12.1% |
Q3 2018 | $5,930,000 | +6.3% | 54,560 | -3.5% | 2.17% | +1.2% |
Q2 2018 | $5,579,000 | -0.8% | 56,535 | -1.6% | 2.14% | -0.3% |
Q1 2018 | $5,623,000 | +3.7% | 57,430 | -1.7% | 2.15% | +10.5% |
Q4 2017 | $5,421,000 | +13.0% | 58,405 | +4.4% | 1.94% | +9.9% |
Q3 2017 | $4,798,000 | +6.9% | 55,921 | +5.1% | 1.77% | +3.9% |
Q2 2017 | $4,489,000 | +0.3% | 53,191 | +1.6% | 1.70% | -1.2% |
Q1 2017 | $4,477,000 | +24.8% | 52,350 | +13.6% | 1.72% | +18.5% |
Q4 2016 | $3,586,000 | +37.8% | 46,075 | +38.8% | 1.45% | +40.4% |
Q3 2016 | $2,603,000 | +30.9% | 33,200 | +68.7% | 1.04% | +30.7% |
Q2 2016 | $1,989,000 | +180.5% | 19,680 | +163.5% | 0.79% | +175.0% |
Q1 2016 | $709,000 | – | 7,470 | – | 0.29% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
WALTER & KEENAN WEALTH MANAGEMENT LLC /IN/ /ADV | 263,188 | $33,896,000 | 13.46% |
ARTHUR M. COHEN & ASSOCIATES, LLC | 263,188 | $33,896,000 | 13.46% |
Defender Capital, LLC. | 127,230 | $17,610,000 | 12.86% |
Eos Focused Equity Management, L.P. | 53,908 | $7,461,000 | 11.12% |
CORTLAND ASSOCIATES INC/MO | 419,035 | $57,999,000 | 10.88% |
Mirova US LLC | 477,368 | $66,072,000 | 8.75% |
Pactiv General Employee Benefit Trust | 579,300 | $80,181,000 | 8.58% |
Riverstone Advisors, LLC | 57,623 | $7,976,000 | 8.07% |
Eversept Partners, LP | 233,957 | $32,419,197 | 8.06% |
Third Point | 3,570,000 | $494,124,000 | 7.88% |